SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
Overall response rate (ORR) for 20–180 μg/kg IV doses was 78% (14/18; 2 unconfirmed); 6/6 responded
at 60 μg/kg IV. ORR for 135–405 μg/kg SC doses was 67% (8/12); 3/4 responded at 405 μg/kg SC.
Responses were noted starting at 1.0 μg/kg, were rapid at median of 1 month (0.2–3), and durable
with median not reached in 36/46 (4 with response 15+ months; longest at 23+ months). Data at higher
doses are immature.
Talquetamab showed encouraging clinical activity with manageable safety in heavily-pretreated
patients with RRMM, supporting monotherapy development and combination approaches.